NuPathe Inc  

(Public, NASDAQ:PATH)   Watch this stock  
Find more results for PATH
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.24
Shares 31.33M
Beta     -
Inst. own 58%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -132.20% -79.84%
Return on average equity -298.54% -865.71%
Employees 14 -
CDP Score - -


7 Great Valley Pkwy Ste 300
MALVERN, PA 19355-1425
United States - Map
+1-610-2320800 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NuPathe Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company’s lead product, Zecuity (sumatriptan iontophoretic transdermal system), was approved by the Food and Drug Administration (FDA) in January 2013 for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch applied to the upper arm or thigh during a migraine. Following application and with a press of a button, Zecuity initiates transdermal delivery (through the skin) of medication, bypassing the gastrointestinal tract.